Studley William R, Lamanna Emma, Nold-Petry Claudia A, Qin Cheng Xue, Bourke Jane E
Biomedicine Discovery Institute, Department of Pharmacology, Monash University, Clayton, VIC, Australia.
Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Respir Res. 2025 Jun 21;26(1):220. doi: 10.1186/s12931-025-03290-x.
Precision-cut lung slices (PCLS) are gaining traction as a versatile ex vivo tool to study mechanisms and treatments for lung diseases. This preparation, in which the major structural elements of the native lung are preserved, bridges the gap between cell and in vivo models allowing researchers to assess integrated functional responses including smooth muscle reactivity, inflammation and tissue remodelling. To date, the application of PCLS to study outcomes relevant to diseases affecting the pulmonary vasculature, such as pulmonary hypertension, is relatively limited compared to those focussed on chronic airway or interstitial lung diseases. This review explores the specific technical requirements for the preparation of PCLS with viable, patent pulmonary arteries, and their application for investigation of mechanisms and treatments related to pulmonary hypertension. Studies characterising vascular responses to contractile agonists in PCLS, particularly in the context of disease-relevant stimuli and models are described, as well as the use of PCLS for the identification of novel vasodilators. This article also outlines current research to prolong PCLS viability and provides directions for future PCLS studies to investigate inflammation and vascular remodelling, with a view to identify therapeutics that address the current limitations of dilator-only treatment of pulmonary hypertension. Overall, the review highlights the importance of PCLS for mechanistic studies and drug development. While PCLS are currently underutilised in the context of pulmonary hypertension, the evidence provided here of the multifaceted functional outcomes that can be investigated using PCLS supports their wider application for understanding disease pathophysiology and validating novel therapeutics.
精密切割肺片(PCLS)作为一种用于研究肺部疾病机制和治疗方法的通用离体工具,正越来越受到关注。这种制备方法保留了天然肺的主要结构元素,弥合了细胞模型和体内模型之间的差距,使研究人员能够评估包括平滑肌反应性、炎症和组织重塑在内的综合功能反应。迄今为止,与专注于慢性气道或间质性肺疾病的研究相比,PCLS在研究与影响肺血管系统的疾病(如肺动脉高压)相关的结果方面的应用相对有限。本综述探讨了制备具有存活且通畅肺动脉的PCLS的具体技术要求,以及它们在研究肺动脉高压相关机制和治疗方法中的应用。描述了表征PCLS中血管对收缩激动剂反应的研究,特别是在与疾病相关的刺激和模型背景下的研究,以及使用PCLS鉴定新型血管扩张剂的研究。本文还概述了目前延长PCLS存活期的研究,并为未来PCLS研究调查炎症和血管重塑提供了方向,以期确定能够解决目前仅使用扩张剂治疗肺动脉高压局限性的治疗方法。总体而言,该综述强调了PCLS在机制研究和药物开发中的重要性。虽然PCLS目前在肺动脉高压研究中未得到充分利用,但本文提供的证据表明,使用PCLS可以研究多方面的功能结果,这支持了它们在理解疾病病理生理学和验证新型治疗方法方面的更广泛应用。